MedPage Today on MSN
Case Study: Encouraging Treatment for Patient With Advanced HR+/HER2- Breast Cancer With Visceral Crisis
Endocrine therapy is generally recommended for patients with HR+/HER2-metastatic breast cancer, with the exception of those ...
Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.
NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R ...
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback